fbpx

Advanced Colorectal Cancer

Tubular Adenocarcinoma of Sigmoid Colon

Male, 63 years

Patient Internal ID: 733100624

ICD-10 code

C18.7 Malignant Neoplasm of Sigmoid Colon

Diagnosis (Incl. Metastases/Stage) and Year

February 2021
Tubular Adenocarcinoma of Sigmoid Colon with Low-Grade Epithelial Dysplasia, Stage 4, (two derivatives) with Unverified Nodules in the Liver.

Previous Treatment

No previous treatment was given. From November 2021, the patient has been receiving Immunotherapy of UCB CIK + IL-2 every 3 weeks.

Prognosis and Survival Expectation

The prognosis remains poor, Advanced Colorectal Cancer median survival is around 30 months. The relative 5-year survival rate of Advanced Colorectal Cancer is 13%.

Treatment Provided

Autologous DCV (9 doses) and CIK (24 doses) with IL-2 over a period of 15 months. Additionally, the patient received Xenogeneic Preventive and Therapeutic Anti-Cancer Vaccine (PTAC) (10 vaccines), Mistletoe Therapy.

Patient Survival/Condition and Year
Date of Review: 20/01/2024

The patient has survived for 35 months since the diagnosis. He attends regular surveillance. In the latest PET/CT scan, no visible changes were reported in the Colon, however, the unverified nodules in the Liver were reported to be increased in volume. The patient has exceeded median survival of mCRC by 5 months. It can therefore be concluded that Immunotherapy has benefited in disease stabilization so far.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.